10 Best Immunotherapy Stocks To Buy Now

Published on October 11, 2022 at 11:54 am by Usman Kabir in Hedge Funds, News

In this article, we discuss 10 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 5 Best Immunotherapy Stocks To Buy Now.

The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the industry. According to a report by market research firm BCC Research, the global market for immunotherapy drugs could be worth more than $204 billion in value by 2025, up from $139 billion in 2020, representing an annual growth rate of close to 8%. The estimates are based on analysis of new products, regulatory scenarios, and the challenges and opportunities affecting market growth.

Within the immunotherapy universe, cancer immunotherapies are the largest market. According to data compiled by the American Cancer Society, of all drug approvals between 2010 and 2018, 27% were cancer therapies, compared with 4% in the 1980s. Despite this explosive growth, cancer remains the leading cause of death globally, accounting for nearly 10 million deaths in 2020. To put this figure into context, the coronavirus pandemic killed about 3 million people in the same year.

Growth Drivers and Challenges Abound for Immunotherapy Marketplace

Investors eager to take advantage of the growth opportunities in the sector should monitor some of the best immunotherapy stocks that include Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV). In recent years, immunotherapy research has evolved to include trials studying combinations such as kill switches, removable protein masks, or linkers that bring immune cells and tumor cells into proximity in order to tamp down side-effects.

There are several reasons that are holding back even faster development within the immunotherapy marketplace. These include the high cost of cancer immunotherapies, strict rules and regulations related to government policies in some regions, manufacturing process related complexities, and concern regarding side effects. The growth drivers, on the other hand, include the increasing prevalence of autoimmune diseases among adults and growing investments in the research and funding of cancer.

Our Methodology

The companies that operate in the immunotherapy sector were selected for the list. In order to provide readers with some additional context for their investment choices, the business fundamentals and analyst ratings for these stocks are also discussed. The latest pipeline drugs of these firms, under various stages of their development, are mentioned as well for further clarity. A database of around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

Best Immunotherapy Stocks To Buy Now

10. Evaxion Biotech A/S (NASDAQ:EVAX)

Number of Hedge Fund Holders: 2

Evaxion Biotech A/S (NASDAQ:EVAX) is a clinical-stage biotech company that engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. It is one of the best immunotherapy stocks to invest in. Evaxion Biotech A/S (NASDAQ:EVAX) recently revealed that it enrolled the first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the US, Europe, and Australia in collaboration with drug giant Merck, which is supplying the trial with its blockbuster drug Keytruda.

On July 18, investment advisory Oppenheimer assumed coverage of Evaxion Biotech A/S (NASDAQ:EVAX) stock with an Outperform rating and a $16 price target. Analyst Jeff Jones issued the ratings update.

At the end of the second quarter of 2022, 2 hedge funds in the database of Insider Monkey held stakes worth $185,000 in Evaxion Biotech A/S (NASDAQ:EVAX), compared to 2 in the previous quarter worth $1.3 million.

Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in Evaxion Biotech A/S (NASDAQ:EVAX), with 333,100 shares worth more than $650,000.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Evaxion Biotech A/S (NASDAQ:EVAX) is one of the best immunotherapy stocks to buy right now.

9. ThermoGenesis Holdings, Inc. (NASDAQ:THMO)

Number of Hedge Fund Holders: 3

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It is one of the top immunotherapy stocks to invest in. The company currently markets a full suite of solutions for automated clinical bio-banking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

On August 11, the company reported earnings for the second quarter of 2022, posting a revenue of $3 million, up more than 37% compared to the revenue over the same period last year. The firm is based in California and was founded in 1986.

At the end of the second quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $68,000 in ThermoGenesis Holdings, Inc. (NASDAQ:THMO). Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in ThermoGenesis Holdings, Inc. (NASDAQ:THMO), with 195,192 shares worth more than $54,000.

8. Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Number of Hedge Fund Holders: 6

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical stage biopharmaceutical company that focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. It is one of the premier immunotherapy stocks to invest in. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) recently entered into an Open Market Sale Agreement with Jefferies, wherein it may issue and sell from time to time shares at a par value of $0.001 per unit. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) also recently reported that the US Food and Drug Administration had removed a clinical hold on a phase 3 trial of a breast cancer treatment, allowing the trial to progress.

On July 12, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock with a $78 price target, predicting that the FLAMINGO-01 breast cancer trial of the firm would proceed as planned.

Among the hedge funds being tracked by Insider Monkey, NewYork-based investment firm Renaissance Technologies is a leading shareholder in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), with 105,159 shares worth more than $891,000. At the end of the second quarter of 2022, 6 hedge funds in the database of Insider Monkey held stakes worth $2.8 million in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), compared to 1 the preceding quarter worth $410,000.

7. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 8

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company that engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It is one of the major immunotherapy stocks to invest in. ImmunityBio, Inc. (NASDAQ:BRX) recently revealed that the drug authorities in the US had accepted for review the company’s biologics license application (BLA) for its agonist N-803, a treatment of bladder cancer carcinoma in situ. The exact indication for N-803 is for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

On August 03, Jefferies analyst Kelly Shi initiated coverage of ImmunityBio, Inc. (NASDAQ:BRX) stock with a Buy rating and lowered price target to $8 from $10, stressing that the price target is lowered to reflect the recent pullback and current market conditions.

At the end of the second quarter of 2022, 8 hedge funds in the database of Insider Monkey held stakes worth $11 million in ImmunityBio, Inc. (NASDAQ:IBRX), compared to 7 the preceding quarter worth $7 million.

6. UroGen Pharma Ltd. (NASDAQ:URGN)

Number of Hedge Fund Holders: 11

UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company that engages in the development and commercialization of novel solutions for specialty cancers and urothelial diseases. It is one of the elite immunotherapy stocks to invest in. UroGen Pharma Ltd. (NASDAQ:URGN) stock has risen in the past week after the company said that the US FDA had authorized an extension of the in-use period for Jelmyto (mitomycin) for pyelocalyceal solution admixture from 8 hours to 96 hours after reconstitution of the product.

On April 27, Berenberg analyst Anita Dushyanth initiated coverage of UroGen Pharma Ltd. (NASDAQ:URGN) stock with a Buy rating and a $20 price target, denoting that there was a considerable opportunity for UroGen’s novel RTGel drug-delivery technology in both high- and low-grade bladder cancers given that bladder cancer has a high rate of recurrence and is currently being treated predominantly with surgery.

Among the hedge funds being tracked by Insider Monkey, Oregon-based investment firm Stonepine Capital is a leading shareholder in UroGen Pharma Ltd. (NASDAQ:URGN), with 1.1 million shares worth more than $9 million. At the end of the second quarter of 2022, 11 hedge funds in the database of Insider Monkey held stakes worth $33 million in UroGen Pharma Ltd. (NASDAQ:URGN), compared to 9 the preceding quarter worth $19 million.

In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best immunotherapy stocks to buy right now according to smart investors.

Click to continue reading and see 5 Best Immunotherapy Stocks To Buy Now.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

10 Best Immunotherapy Stocks To Buy Now

Published on October 11, 2022 at 11:54 am by Usman Kabir in Hedge Funds, News

Growth Drivers and Challenges Abound for Immunotherapy Marketplace

Best Immunotherapy Stocks To Buy Now

10. Evaxion Biotech A/S (NASDAQ:EVAX)

9. ThermoGenesis Holdings, Inc. (NASDAQ:THMO)

8. Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

7. ImmunityBio, Inc. (NASDAQ:IBRX)

6. UroGen Pharma Ltd. (NASDAQ:URGN)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

10 Best Immunotherapy Stocks To Buy Now

Published on October 11, 2022 at 11:54 am by Usman Kabir in Hedge Funds, News

Share

Growth Drivers and Challenges Abound for Immunotherapy Marketplace

Best Immunotherapy Stocks To Buy Now

10. Evaxion Biotech A/S (NASDAQ:EVAX)

9. ThermoGenesis Holdings, Inc. (NASDAQ:THMO)

8. Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

7. ImmunityBio, Inc. (NASDAQ:IBRX)

6. UroGen Pharma Ltd. (NASDAQ:URGN)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff